Description: Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers Multicore, a suite of integrated synthetic methods that gives access to complex drug-like molecules; and ionX, an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development, as well as contract research services. The company has a collaborative partnership with Merck & Co., Inc. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
Home Page: www.bionomics.com.au
200 Greenhill Road
Eastwood,
SA
5063
Australia
Phone:
61 8 8150 7400
Officers
| Name | Title |
|---|---|
| Dr. Errol B. De Souza Ph.D. | Exec. Chairman |
| Mr. Adrian Hinton BEC, F.C.A. | Acting Chief Financial Officer |
| Mr. Connor Bernstein M.Sc. | VP of Strategy & Corp. Devel. |
| Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. | Consultant Chief Medical Officer of Clinical Neuroscience |
| Ms. Suzanne Irwin B.Com., FCIS | Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 23.5849 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2444 |
| Price-to-Sales TTM: | 8.2931 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |